AMPIVIEW® RNA probes
Enabling Your Projects 
GMP Services
Bulk Solutions
Research Travel Grant
Have You Published Using an Enzo Product?
Mcl-1 is a member of the Bcl-2 family that possesses anti-apoptotic activity. Mcl-1 is an immediate-early gene activated by the GMCSF as well as IL-3 signaling pathways and plays an important role in the viability response of these cytokines. Similar to all Bcl-2 family members, Mcl-1 contains BH1, BH2, and BH3 domains; however, unlike other members of this family, Mcl-1 has an extended N-terminal domain rich in PEST sequences, which probably accounts for the short half-life of this protein.
Shipping: Available products typically ship within 24/48h, via priority shipping.
Do you need support? Contact Customer Service or Technical Support.
Online Account
Access or Create Your Account
This antibody is covered by our Worry-Free Guarantee.
Immunofluorescent analysis (confocal) staining of HeLa cells using Mcl-1 pAb (green); nuclei are stained in blue pseudocolor using DRAQ5.
Immunohistochemistry analysis of human breast cancer tissue with Mcl-1 pAb.
Western blot analysis of Mcl-1, pAb: Lane 1: MW marker, Lane 2: HeLa, Lane 3: 3T3, Lane 4: PC-12, Lane 5: MDCK, Lane 6: RK-13.
BET inhibitors/-degraders change the protein expression and induce cell death in DLBCL. a) Induction of cell death [%] after 24 h treatment with the indicated BET inhibitors/-degraders at 1µM measured by AnnexinV-FITC/PI staining and flow cytometry [data are shown as mean + standard deviation (SD) with n = 3]. b-d) Western Blot of BRD4, c-MYC and BCL2-familiy proteins after 24 h treatment with the indicated BET inhibitors/-degraders at 1µM in b) SUDHL2, c) TMD8 and d) U2932 cells with GAPDH serving as housekeeping control [one representative blot out of three independent experiments is shown]
Image collected and cropped by CiteAb under a CC-BY license from the following publication: Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell Commun Signal (2024)
BET inhibitors/-degraders change the protein expression and induce cell death in DLBCL. a) Induction of cell death [%] after 24 h treatment with the indicated BET inhibitors/-degraders at 1µM measured by AnnexinV-FITC/PI staining and flow cytometry [data are shown as mean + standard deviation (SD) with n = 3]. b-d) Western Blot of BRD4, c-MYC and BCL2-familiy proteins after 24 h treatment with the indicated BET inhibitors/-degraders at 1µM in b) SUDHL2, c) TMD8 and d) U2932 cells with GAPDH serving as housekeeping control [one representative blot out of three independent experiments is shown]
Image collected and cropped by CiteAb under a CC-BY license from the following publication: Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell Commun Signal (2024)
Viability and protein levels are influenced by selected BET inhibitors/-degraders. a) Cell viability determined by CTG assay after 48 h treatment with the indicated BET inhibitors/ degraders in ABC and CGB cell lines [data are shown as mean +/- standard deviation (SD) with n = 3]. b) Western Blot of BRD4 and BCL2 familiy proteins in SUDHL2, TMD8 and Pfeiffer cells treated with JQ1 [1µM], ABBV-075 [SUDHL2 and Pfeiffer 100nM/TMD8 300nM], ARV-825 [SUDHL2 100nM/TMD8 30nM/Pfeiffer 10 nM] and dBET6 [SUDHL2 100nM/TMD8 30nM/Pfeiffer 10 nM]. Cell viability determined by AnnexinV-FITC/PI staining and flow cytometry after 24 h incubation is indicated below the Western blot [one representative blot out of three independent experiments is shown]
Image collected and cropped by CiteAb under a CC-BY license from the following publication: Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell Commun Signal (2024)
| Regulatory Status |
RUO – Research Use Only |
|---|
